Stock-Based Compensation: The estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors.
Seelos Therapeutics, Inc. (SEELQ) had Stock-Based Compensation of $3.99M for the most recently reported fiscal year, ending 2023-12-31.
| Income Statement Financials | |
$2.20M |
|
$-37.88M |
|
-- |
|
$2.20M |
|
$42.70M |
|
$-40.50M |
|
$2.62M |
|
$-37.88M |
|
$-37.88M |
|
$-37.88M |
|
$-37.88M |
|
$-37.88M |
|
$-37.88M |
|
$-40.50M |
|
$-40.50M |
|
0.04M |
|
0.04M |
|
$-989.44 |
|
$-989.44 |
|
| Balance Sheet Financials | |
$5.40M |
|
-- |
|
$0.01M |
|
$5.42M |
|
$38.93M |
|
-- |
|
-- |
|
$38.93M |
|
$-33.51M |
|
$-33.51M |
|
$-33.51M |
|
0.08M |
|
| Cash Flow Statement Financials | |
$-23.91M |
|
-- |
|
$11.38M |
|
$15.53M |
|
$3.00M |
|
$-12.54M |
|
|
Stock-Based Compensation |
$3.99M |
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.14 |
|
-- |
|
-- |
|
-- |
|
-0.42 |
|
100.00% |
|
-1838.36% |
|
-1838.36% |
|
-1838.36% |
|
-1719.56% |
|
-1719.56% |
|
$-23.91M |
|
-- |
|
-- |
|
-- |
|
0.41 |
|
-- |
|
-- |
|
-- |
|
113.05% |
|
113.05% |
|
-699.19% |
|
113.05% |
|
$-437.90 |
|
$-624.64 |
|
$-624.64 |
|